top of page

FDA to re-review application for AstraZeneca’s hyperkalaemia treatment

The US Food and Drug Administration (FDA) has accepted a complete re-submission of a new drug application for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary ofAstraZeneca. The FDA has indicated that this is a complete class 2 response.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page